All In MedTech

Device Trial Radar · NCT04468633

The Baerveldt Versus ClearPath Comparison Study

Last checked: Nov 19, 2026Latest source record: Sep 5, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

76

Actual

Start

Dec 17, 2020

Primary completion

Jun 29, 2023

Study completion Jun 29, 2023

Sponsor

Lead sponsor
Duke UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jul 13, 2020

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 18 years, up to 90 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized prospective study of post-operative surgical outcomes and complication rates in patients with a Baerveldt 350 implant vs the Ahmed ClearPath implant. Each subject will be randomized to the Baerveldt group or ClearPath group at the time of consent for the study.

Conditions

  • Glaucoma

Interventions

  • Baerveldt 350 implantDevice

    The Baerveldt implant is an FDA-approved silicone, non-valved implant.

  • Ahmed ClearPath 350 implantDevice

    The Ahmed ClearPath is a non-valved glaucoma drainage device.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Intraocular Pressure (IOP)Time frame: Baseline, Day 1, Week 1, Week 4, Week 6, Month 3, Month 6, and Year 1
  2. Number of Participants Who Experienced a ComplicationTime frame: Up to Year 1

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Duke Eye Center

    Durham, North Carolina

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.